NHI covers additional indications of Remicade

Janssen Korea said Wednesday that the additional indications of its TNF-alpha inhibitor Remicade, which was approved by the Korea Food and Drug Administration in 2000, has been further covered by national health insurance from April 1.

Under the recently revised health insurance scheme, Remicade at a dose of 10 mg/kg can be indicated for reducing signs and symptoms and inducing and maintain...